GYRE

Gyre Therapeutics, Inc. (NASDAQ:GYRE) is a pharmaceutical company founded in 2002 and headquartered in San Diego, California. The company went public in 2006 and operates as a subsidiary of GNI USA, Inc. Gyre specializes in developing and commercializing small-molecule drugs that target organ fibrosis, a medical condition where healthy tissue is replaced by scar tissue, leading to organ dysfunction. The company has successfully brought its lead drug to market and maintains an active pipeline of treatments for various fibrotic diseases affecting the lungs, liver, and other organs.